-
Product Insights
Primary CNS Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary CNS Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary CNS Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TCK-276 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TCK-276 in Rheumatoid Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TCK-276 in Rheumatoid Arthritis Drug Details: TCK-276 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bumetanide in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bumetanide in Parkinson's DiseaseDrug Details:Bumetanide is under development for the treatment of Parkinson’s disease. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satraplatin in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satraplatin in T-Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Satraplatin in T-Cell Lymphomas Drug Details:Satraplatin is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABP-450 in Spasmodic Torticollis (Cervical Dystonia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABP-450 in Spasmodic Torticollis (Cervical Dystonia) Drug Details: ABP-450 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satraplatin in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satraplatin in Primary CNS Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Satraplatin in Primary CNS LymphomaDrug Details:Satraplatin is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-01488 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TT-01488 in Diffuse Large B-Cell Lymphoma Drug Details:TT-01488 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GC-101 in Non-Small Cell Lung Cancer Drug Details:GC-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirvetuximab Soravtansine in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirvetuximab Soravtansine in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirvetuximab Soravtansine in Endometrial Cancer Drug Details: Mirvetuximab Soravtansine (Elahere, Mirvetuximab...
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.